Trial Information
A Prospective Randomized Trial of Regional Versus Systemic Continuous Gemcitabine Chemotherapy in the Treatment of Unresectable Pancreatic Cancer
Inclusion Criteria:
- Signed written informed consent
- Karnofsky score > 60,
- Expected survival > 3 months,
- Liver, kidney function and routine blood test within normal range
- No serious cardiopulmonary dysfunction
- No acute infection
Exclusion Criteria:
- Pregnant or lactating women
- Uncontrolled internal diseases
- Past or the presence of other malignancy
- Those who had received immunosuppressive therapy
Type of Study:
Interventional
Study Design:
Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment
Outcome Measure:
overall surviva
Outcome Time Frame:
36 months
Safety Issue:
No
Principal Investigator
Guohong Han, MD
Investigator Role:
Principal Investigator
Investigator Affiliation:
Xijing Hospital of Digestive Diseases, Fourth Military Medical University
Authority:
China: Ethics Committee
Study ID:
XHDD 003
NCT ID:
NCT01665625
Start Date:
August 2012
Completion Date:
February 2016
Related Keywords:
- Unresectable Pancreatic Cancer
- Pancreatic cancer
- Intra-arterial infusion
- Gemcitabine
- Pancreatic Neoplasms